Further extensive investigations including large-scale, longitudinal clinical trials are paramount to justify the diagnostic and therapeutic potential of FABP4 in maternal–fetal metabolic diseases alongside rigorous safety assessments of its therapeutic application. The gene discussed is FABP4; the disease is metabolic disease.